Inhibition of macrophage migration inhibitory factor attenuates bleomycin-induced murine pulmonary fibrosis via the MAPK pathway
Authors:
Open Access
- 16 May 2026
- journal article
- Published by Springer Nature in Respiratory Research
- Vol. 27 (1)
Abstract
Idiopathic Pulmonary Fibrosis (IPF) is a chronic progressive disease marked by excessive extracellular matrix deposition and deteriorating lung function. Although macrophage migration inhibitory factor (MIF) has been implicated in pulmonary fibrosis, the downstream mechanisms-particularly whether MIF drives fibrosis through its receptor CD74-remain insufficiently understood. This study investigated whether MIF/CD74 signaling promotes fibroblast activation through specific downstream pathways that regulate proliferation and matrix production. Single-cell RNA sequencing and ELISA were used to characterize MIF-CD74 interactions and circulating MIF levels in IPF patients. Bleomycin-induced fibrosis models were established using C57BL/6J mice, Mif⁻/⁻ mice, and the MIF inhibitor 4-IPP. Macrophage-fibroblast co-culture systems were treated with bleomycin, 4-IPP, or CD74 shRNA. Lung injury, fibrosis, and signaling activation were assessed by histology, qRT-PCR, Western blotting, and functional assays. scRNA-seq identified MIF-CD74 as a dominant macrophage-fibroblast signaling axis in fibrotic lungs, and serum MIF levels were elevated in IPF patients. In mice, bleomycin markedly increased MIF and CD74 expression and activated MAPK signaling. Genetic deletion or pharmacologic inhibition of MIF attenuated collagen deposition, improved lung architecture, and reduced profibrotic and inflammatory signaling. In vitro, MIF promoted fibroblast proliferation, migration, and matrix synthesis, whereas CD74 knockdown or MIF inhibition significantly attenuated fibroblast profibrotic responses. MIF promotes pulmonary fibrosis by activating CD74-dependent MAPK signaling in fibroblasts, enhancing their proliferation and extracellular matrix production. Targeting the MIF/CD74 axis reduces tissue remodeling and represents a promising therapeutic strategy for IPF.Keywords
Funding Information
- High Level Public Health Technology Talent Construction Project (DL-02-21)
This publication has 43 references indexed in Scilit:
- Emerging role of immune cells as drivers of pulmonary fibrosisPharmacology & Therapeutics, 2023
- TREM2 Insufficiency Protects against Pulmonary Fibrosis by Inhibiting M2 Macrophage PolarizationInternational Immunopharmacology, 2023
- Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosisEnvironment International, 2022
- Macrophage migration inhibitory factor (MIF): A multifaceted cytokine regulated by genetic and physiological strategiesPharmacology & Therapeutics, 2022
- Impact of Antifibrotic Therapy on Mortality and Acute Exacerbation in Idiopathic Pulmonary FibrosisChest, 2021
- The Smad3-miR-29b/miR-29c axis mediates the protective effect of macrophage migration inhibitory factor against cardiac fibrosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2019
- Evolving complexity of MIF signalingCellular Signalling, 2019
- Inflammation and immunity in IPF pathogenesis and treatmentRespiratory Medicine, 2019
- Resveratrol inhibits pulmonary fibrosis by regulating miR-21 through MAPK/AP-1 pathwaysBiomedicine & Pharmacotherapy, 2018
- Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74Cellular Signalling, 2011